The press conference on the adjustment of the 2022 National Reimbursement Drug List was held on Jan 18. The National Medical Insurance Administration released the adjustment and new version of the NRDL.

According to the press conference, the healthcare negotiations fully support the treatment of COVID-19 infection. Two drugs, Azvudine Tablets and Qingfei Detoxification Granules, with a price reduction through negotiations, have been officially included in the NRDL and it is also the third year that drugs for treatment of COVID-19 have been included.